HYHirofumi Yoshino

Hirofumi Yoshino

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hirofumi Yoshino has a total of 121 co-authors. Here are the top co-authors by number of shared publications:

  • Takashi Sakaguchi

    Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Japan

    14 shared publications
  • Hideki Enokida

    Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan

    13 shared publications
  • Ryosuke Matsushita

    Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan

    11 shared publications
  • Shuichi Tatarano

    Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Japan

    11 shared publications
  • Yasutoshi Yamada

    Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Japan

    11 shared publications
  • Hideki Enokida

    Department of Urology, Graduate School of Medical and Dental Sciences Kagoshima University Kagoshima Japan

    10 shared publications

Latest Publications

  • Open Access

    Ruptured Retroperitoneal Müllerian Cyst in an Adolescent Female: A Case Report

    by Takashi Sakaguchi, Shuichi Tatarano, Mari Kirishima, Junya Arima, Akihiko Mitsuke, Toru Kiire, Satoru Inoguchi, Ryosuke Matsushita, Hirofumi Yoshino, Hideki Enokida

    Introduction: A retroperitoneal Müllerian cyst is extremely rare. We report our experience treating an adolescent female who presented with a ruptured retroperitoneal Müllerian cyst. Case Presentation: A 15‐year‐old girl presented with the sudden onset of right lower abdominal pain after coughing. Computed tomography and magnetic resonance imaging revealed a multilocular cystic lesion in the right retroperitoneum with findings suggestive of rupture. Emergency laparoscopic resection was performed given her young age, severe symptoms, the risk of re‐rupture, and the inability to exclude malignancy. The histopathologic examination confirmed a retroperitoneal Müllerian cyst with no evidence of malignancy. Conclusion: Emergency laparoscopic resection enabled a definitive diagnosis and successful treatment of a ruptured retroperitoneal Müllerian cyst.

  • Open Access

    Evaluation of Candidate Urinary microRNAs in Upper Tract Urothelial Carcinoma: A Prospective Multicenter Biomarker Study (JCOG1403A1)

    by Shuichi Tatarano, Hideki Enokida, Hiroyuki Nishiyama, Takahiro Kojima, Hirofumi Yoshino, Takahiko Mitsui, Akihiro Ito, Tomonori Habuchi, Keisuke Kanato, Hiroshi Kitamura

    Objectives: To evaluate the clinical associations of candidate urinary microRNAs (miRNAs) in patients with upper tract urothelial carcinoma (UTUC), including their ability to discriminate patients with UTUC from healthy controls and their associations with relapse-free survival (RFS). Methods: This prospective multicenter ancillary study of the JCOG1403 trial (JCOG1403A1 study) included 45 patients with UTUC and 16 healthy controls. Four candidate miRNAs (miR-130b, miR-182, miR-191, and miR-200a) were selected based on prior exploratory sequencing analysis. Urinary cell fractions were isolated by cell sorting, and miRNA expression was quantified by stem-loop RT-qPCR. The ability of urinary miRNAs to discriminate patients with UTUC from healthy controls, their associations with clinicopathological characteristics, and their associations with RFS were evaluated. Results: Among the candidate miRNAs, miR-191 and miR-200a showed significantly increased expression in patients with UTUC and demonstrated favorable discrimination between patients with UTUC and healthy controls. The combined miR-191/miR-200a model showed the highest discriminatory performance (area under the curve, 0.888). Urine cytology was positive in 33.3% of evaluable patients, whereas urinary miR-191 and miR-200a were detectable in 78.6% and 85.7% of patients with negative/suspicious cytology, respectively. Preoperative urinary miR-182 and miR-191 detectability was significantly associated with pathological tumor stage. In exploratory prognostic analyses, patients with detectable postoperative urinary miR-130b had significantly shorter RFS (log-rank p = 0.0455); however, the association was not statistically significant in multivariable Cox regression analysis (hazard ratio 2.76, 95% confidence interval 0.84–9.05, p = 0.094). Conclusions: Urinary miR-191 and miR-200a showed potential for discriminating patients with UTUC from healthy controls and may complement urine cytology, particularly in patients with negative/suspicious cytology. The association between postoperative urinary miR-130b detectability and RFS should be considered exploratory and requires further validation.

  • Open Access

    MEK1 as a Synthetic Lethal Target with Cabozantinib in Renal Cell Carcinoma: Insights from CRISPR/Cas9 Screening

    by Hirofumi Yoshino, Ikumi Fukuda, Hideki Enokida, Naohiko Seki, Yusuke Goto

    Background/Objectives: Cabozantinib is a tyrosine kinase inhibitor that primarily targets MET. It has become an important drug in the treatment of renal cell carcinoma (RCC); however, many patients do not respond to cabozantinib treatment and there is no effective next-line therapy. In this study, we identified molecular-targeted drugs that exhibit synergistic effects with cabozantinib using CRISPR/Cas9 screening. Methods: A kinome-wide synthetic lethal CRISPR/Cas9 screen was used to identify target molecules using 786-o RCC cells. A library was generated, and treatment with vehicle or cabozantinib was carried out, followed by next-generation sequencing to identify candidate genes. A combination index based on the Chou–Talalay method was used to evaluate the synergistic effect of cabozantinib through cell viability assays. Xenograft assays were conducted to determine the effect in vivo. Results: CRISPR/Cas9-based screening revealed four genes (MEK1, DCLK1, DYRK3, and FGFR1) that were candidates for synthetic lethality by cabozantinib in RCC cells. We focused on MEK1 because the MEK1 inhibitor cobimetinib has been approved for melanoma treatment. In a cell proliferation assay using 786-o and A498 RCC cells, the combination of cobimetinib and cabozantinib exhibited a synergistic effect. A xenograft assay also revealed a significant synergistic effect of cobimetinib and cabozantinib. Conclusions: CRISPR/Cas9 screening identified MEK1 as a candidate for a synthetic lethal target with cabozantinib in RCC. The combined inhibition of MET/VEGFR and MEK1 suppressed compensatory MAPK reactivation and downregulated the PI3K-Akt pathway, including the survival-associated genes PPP2R3B and ATF6B, and produced significant tumor growth suppression in vivo. These findings highlight the potential of cabozantinib plus cobimetinib, an already-FDA-approved MEK inhibitor, as a readily translatable combination strategy to overcome cabozantinib resistance in RCC.

  • Open Access

    Therapeutic strategies for MMAE ‐resistant bladder cancer through DPP4 inhibition

    by Gang Li, Shuichi Tatarano, Hirofumi Yoshino, Saeki Saito, Mitsuhiko Tominaga, Junya Arima, Ikumi Fukuda, Takashi Sakaguchi, Ryosuke Matsushita, Yasutoshi Yamada, et al.

    Monomethyl auristatin E (MMAE) is used as the cytotoxic payload for enfortumab vedotin (EV) in the treatment of locally advanced and metastatic bladder cancer (BC). However, the development of resistance to MMAE in BC is a therapeutic problem. To explore the mechanism of resistance to MMAE in BC, we established MMAE‐resistant BC cells (MR‐BCs). RNA sequencing analysis showed that the expression of dipeptidyl peptidase 4 (DPP4, also called CD26) increased significantly in MR‐BCs compared with parental BC cells. Knock down of DPP4 expression using small interfering RNA inhibited the viability of MR‐BCs. In addition, the DPP4 inhibitor sitagliptin suppressed the proliferation, migration, and invasion of BC cells, and cotreatment with MMAE effectively induced cell apoptosis, arrested cells in the G 2 M phase of the cell cycle, increased reactive oxygen species production by inhibiting the AKT pathway, and significantly inhibited the in vivo growth of MMAE‐resistant cells. This study provides insights into the use of DPP4 inhibitors as a treatment strategy for MMAE‐resistant BC.


  • Open Access

    Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study

    by Junya Arima, Hirofumi Yoshino, Shuichi Tatarano, Akihiko Mitsuke, Yoichi Osako, Takashi Sakaguchi, Ryosuke Matsushita, Satoru Inoguchi, Yasutoshi Yamada, Hideki Enokida

    Background: Combining the probiotic product CBM588 with immune checkpoint inhibitors (ICIs) has shown improved prognosis in several cancers. Pembrolizumab alone as a second‐line treatment for urothelial cancer (UC) extends prognosis by only 3 months.Aims: This is a retrospective study that examined the effects of CBM588 combined with pembrolizumab in advanced UC.Methods and Results: The study included 44 patients who had recurrence or progression after first‐line chemotherapy with cisplatin or carboplatin. The study compared 33 patients treated with pembrolizumab alone and 11 patients treated with CBM588 plus pembrolizumab over a median observation period of 12 months. The combination of CBM588 and pembrolizumab significantly improved progression‐free survival (PFS; p = 0.004) and overall survival (OS; p = 0.02). Multivariate analysis identified CBM588 as a significant prognostic factor for both PFS (hazard ratio: 0.074, p = 0.0008) and OS (hazard ratio: 0.105, p = 0.0056).Conclusion: These results suggest the effectiveness of the CBM588 combination with ICI treatment in UC.


  • Open Access

    Targeting Heat Shock Transcription Factor 4 Enhances the Efficacy of Cabozantinib and Immune Checkpoint Inhibitors in Renal Cell Carcinoma

    by Saeki Saito, Hirofumi Yoshino, Seiya Yokoyama, Mitsuhiko Tominaga, Gang Li, Junya Arima, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, et al.

    Recently, immune checkpoint inhibitors (ICIs) and cabozantinib, a tyrosine kinase inhibitor (TKI), have been used to treat renal cell carcinoma (RCC); the combination of these agents has become a standard treatment for RCC. TKIs generally target vascular endothelial growth factor. However, cabozantinib is characterized by its targeting of MET. Therefore, cabozantinib can be used as a late-line therapy for TKI-resistant RCC. According to data from The Cancer Genome Atlas (TCGA), heat shock transcription factor 4 (HSF4) expression is higher in RCC tissues than in normal renal tissues. HSF4 binds to the MET promoter in colorectal carcinoma to enhance MET expression and promote tumor progression. However, the functional role of HSF4 in RCC is unclear. We performed loss-of-function assays of HSF4, and our results showed that HSF4 knockdown in RCC cells significantly decreased cell functions. Moreover, MET expression was decreased in HSF4-knockdown cells but elevated in sunitinib-resistant RCC cells. The combination of cabozantinib and HSF4 knockdown reduced cell proliferation in sunitinib-resistant cells more than each monotherapy alone. Furthermore, HSF4 knockdown combined with an ICI showed synergistic suppression of tumor growth in vivo. Overall, our strategy involving HSF4 knockdown may enhance the efficacy of existing therapies, such as cabozantinib and ICIs.


  • Open Access

    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification

    by Wataru Fukumoto, Shunsuke Okamura, Motoki Tamai, Junya Arima, Ichiro Kawahara, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoshi Sugita, Ryosuke Matsushita, et al.

    Chemotherapy including cisplatin is recommended for the treatment of advanced bladder cancer, but its effectiveness is limited due to the acquisition of drug resistance. Although several mechanisms of cisplatin resistance have been reported, there are still many unknowns, and treatment of cisplatin-resistant bladder cancer remains difficult. Accordingly, in this study, we aimed to identify and characterize microRNAs involved in cisplatin resistance. Small RNA sequencing analysis was performed to search for microRNAs related to cisplatin resistance. The identified microRNAs were then characterized using gain-of-function studies, sensitivity analysis, target gene analysis, and cellular assays. We identified miR-424-5p as a candidate microRNA that was downregulated in cisplatin-resistant strains compared with parental strains. Notably, in gain-of-function studies, miR-424-5p suppressed the proliferative ability of cisplatin-resistant bladder cancer (CDDP-R BC). Furthermore, miR-424-5p restored sensitivity to cisplatin. RNA sequence analysis revealed seven candidate genes targeted by this microRNA. Among them, cyclin E1 (CCNE1) was chosen for subsequent analyses because its expression was upregulated in cisplatin-resistant cells compared with parental cells and because recent studies have shown that CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. Therefore, we performed functional analysis using the PKMYT1 inhibitor RP-6306 and demonstrated that RP-6306 inhibited cell growth through suppression of mitotic entry and restored cisplatin sensitivity in CDDP-R BC. Overall, our findings provided insights into the development of novel therapeutic strategies for CDDP-R BC.


  • Open Access

    Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine‐ and cisplatin‐resistant models

    by Ichiro Kawahara, Hirofumi Yoshino, Wataru Fukumoto, Junya Arima, Saeki Saito, Gang Li, Ikumi Fukuda, Akihiko Mitsuke, Takashi Sakaguchi, Satoru Inoguchi, et al.

    Gemcitabine plus cisplatin (GC) combination chemotherapy is the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, most cases develop resistance to this therapy. We investigated whether drug resistance could be targeted through metabolic reprogramming therapies. Metabolomics analyses in our lab's gemcitabine‐ and cisplatin‐resistant cell lines revealed increased phosphoglycerate dehydrogenase (PHGDH) expression in gemcitabine‐resistant cells compared with parental cells. Isocitrate dehydrogenase 2 (IDH2) gain of function stabilized hypoxia‐inducible factor1α (HIF1α) expression, stimulating aerobic glycolysis. In gemcitabine‐resistant cells, elevated fumaric acid suppressed prolyl hydroxylase domain‐containing protein 2/Egl nine homolog 1 (PHD2) and stabilized HIF1α expression. PHGDH downregulation or inhibition in gemcitabine‐resistant BC cells inhibited their proliferation, migration, and invasion. Cisplatin‐resistant cells showed elevated fatty acid metabolism, upregulating fatty acid synthase (FASN) downstream of tyrosine kinase. Using the fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib, we inhibited malonyl‐CoA production, which is crucial for fatty acid synthesis, and thereby suppressed upregulated HIF1α expression. Combination treatment with NCT503 and erdafitinib synergistically suppressed tumor cell proliferation and induced apoptosis in vitro and in vivo. Understanding these mechanisms could enable innovative BC therapeutic strategies to be developed.


  • Open Access

    LncRNA BCYRN1 as a Potential Therapeutic Target and Diagnostic Marker in Serum Exosomes in Bladder Cancer

    by Junya Arima, Hirofumi Yoshino, Wataru Fukumoto, Ichiro Kawahara, Saeki Saito, Gang Li, Ikumi Fukuda, Sayaka Iizasa, Akihiko Mitsuke, Takashi Sakaguchi, et al.

    Bladder cancer (BC) is a common genitourinary malignancy that exhibits silent morbidity and high mortality rates because of a lack of diagnostic markers and limited effective treatments. Here, we evaluated the role of the lncRNA brain cytoplasmic RNA 1 (BCYRN1) in BC. We performed loss-of-function assays to examine the effects of BCYRN1 downregulation in T24 and BOY BC cells. We found that BCYRN1 downregulation significantly inhibited the proliferation, migration, invasion, and three-dimensional spheroid formation ability and induced apoptosis in BC cells. Additionally, gene set enrichment analysis (GSEA) using RNA sequences from tumor fractions showed that BCYRN1 downregulation decreased the expression of mRNAs associated with the cell cycle. These findings were supported by observations of G2/M arrest in flow cytometry assays. Finally, we examined the expression of serum exosomal BCYRN1 as a biomarker. Clinically, BCYRN1 expression in serum exosomes from patients with BC (n = 31) was significantly higher than that in healthy donors (n = 19; mean difference: 4.1-fold higher, p < 0.01). Moreover, in patients who had undergone complete resection of BC, serum exosomal BCYRN1 levels were significantly decreased (n = 8). Thus, serum exosomal BCYRN1 may be a promising diagnostic marker and therapeutic target in patients with BC.


  • A high dose KRP203 induces cytoplasmic vacuoles associated with altered phosphoinositide segregation and endosome expansion

    by Satoshi Kofuji, Kara Wolfe, Kazutaka Sumita, Shun Kageyama, Hirofumi Yoshino, Yoshihisa Hirota, Aki Ogawa-Iio, Hirotaka Kanoh, Mika Sasaki, Kaori Kofuji, et al.